Edgewise Therapeutics
Chris Dufton serves as the Vice President of Clinical Development and Operations at Edgewise Therapeutics, where responsibilities include leading development operations for a cardiology program focused on cardiac myosin modulators. Prior to this role, Chris held the position of Senior Vice President of Clinical Development at InCarda Therapeutics, specializing in novel inhalation treatments for cardiovascular conditions. Chris also contributed to ARCA biopharma as Vice President of Clinical Development, where the focus was on precision medicine in cardiovascular therapies. As a consultant at Rubicon Sciences LLC, Chris provided strategic insights for clinical, regulatory, and business development in the biotech industry. Chris began a career in clinical research at Gilead Sciences Inc, leading the post-launch development of ambrisentan. Academic credentials include a PhD in Molecular, Cellular, and Developmental Biology from the University of Colorado Boulder and graduate studies in Immunology and Pharmacology at the University of Colorado School of Medicine.
This person is not in any teams
This person is not in any offices
Edgewise Therapeutics
1 followers
Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it’s Series B financing round which will support the advancement of Edgewise Therapeutic’s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company’s pipeline. The company’s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.